Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 09 Dec 2017 Results assessing tolerability and toxicity presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 10 Jun 2017 Biomarkers information updated
- 23 Nov 2016 Planned primary completion date changed from 1 Mar 2019 to 1 Jun 2019.